Growth hormone deficiency and growth-hormone secretagogue pharmacology — compounds assessed
The 10 compounds the Institute assesses in growth hormone deficiency and growth-hormone secretagogue pharmacology.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide)1 contributing trialfull monograph
A peak growth hormone below 16 ng/mL after 100 µg intravenously supports severe adult growth-hormone deficiency in the approved Japanese diagnostic criteria — The diagnostic evidence base is adequate and the compound holds a marketing authorisation for it…
Moderate -
A luteinising hormone rise after gonadorelin distinguishes pituitary from hypothalamic causes of hypogonadotropic hypogonadism — The diagnostic evidence base is established and underpins the marketing authorisations.
Moderate -
Diagnostic use as a probe of hypothalamic-pituitary-gonadal function — The diagnostic application is the best-established use.
Moderate -
Peak stimulated growth hormone response used diagnostically; a peak below 5 µg/L after sermorelin supports pituitary rather than hypothalamic origin of deficiency — The evidence base supports a diagnostic application. The Institute found no adequately powered…
Moderate -
IGF-1 rose by a mean of 81 ng/mL, with 34 % of participants exceeding the upper limit of normal at some point — IGF-1 monitoring is required; the proportion exceeding the reference range is the reason.
Moderate -
Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex2 contributing trialsfull monograph
Mean IGF-1 increased 1.5- to 3.0-fold above baseline and remained elevated for 6 to 11 days after a single dose in a phase 1 study of 11 participants — A genuine phase 1 pharmacodynamic result exists and the Institute reports it. It establishes that the…
Low -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide)1 contributing trialfull monograph
Dose-dependent acute growth-hormone release with attenuation on repeated administration — Historical human pharmacodynamic data exist. No therapeutic outcome trial does.
Low -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide)2 contributing trialsfull monograph
Marked acute growth-hormone release; the response attenuates substantially over 8 to 16 weeks of continuous administration — Tachyphylaxis is the defining clinical limitation and is documented in the historical literature.
Low -
Growth-hormone secretagogue, selective ghrelin receptor agonist (pentapeptide)2 contributing trialsfull monograph
Dose-dependent growth-hormone release demonstrated in preclinical models and in early human study — The preclinical pharmacology is well characterised. Human data are limited to early-phase work.
Low -
No randomised human evidence identified for this analogue — No trial of LR3 IGF-1 in any human population was located.
Very low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998;139(5):552–561. doi:10.1530/eje.0.1390552 · PMID 9849822
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.